image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 0.9251
-0.783 %
$ 8.26 M
Market Cap
-0.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one POAI stock under the worst case scenario is HIDDEN Compared to the current market price of 0.925 USD, Predictive Oncology Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one POAI stock under the base case scenario is HIDDEN Compared to the current market price of 0.925 USD, Predictive Oncology Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one POAI stock under the best case scenario is HIDDEN Compared to the current market price of 0.925 USD, Predictive Oncology Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart POAI

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
1.62 M REVENUE
-8.78%
-10.9 M OPERATING INCOME
22.33%
-10.9 M NET INCOME
22.34%
-11 M OPERATING CASH FLOW
16.79%
-9.51 K INVESTING CASH FLOW
96.85%
3.94 M FINANCING CASH FLOW
2545.57%
110 K REVENUE
-81.96%
-2.29 M OPERATING INCOME
-7.62%
-2.44 M NET INCOME
-16.28%
-986 K OPERATING CASH FLOW
52.17%
625 K INVESTING CASH FLOW
0.00%
2.5 M FINANCING CASH FLOW
1376.81%
Balance Sheet Predictive Oncology Inc.
image
Current Assets 2.23 M
Cash & Short-Term Investments 735 K
Receivables 746 K
Other Current Assets 746 K
Non-Current Assets 2.75 M
Long-Term Investments 0
PP&E 2.43 M
Other Non-Current Assets 313 K
14.77 %14.99 %15.00 %48.95 %6.29 %Total Assets$5.0m
Current Liabilities 3.59 M
Accounts Payable 1.14 M
Short-Term Debt 1.15 M
Other Current Liabilities 1.31 M
Non-Current Liabilities 1.58 M
Long-Term Debt 1.56 M
Other Non-Current Liabilities 23.5 K
22.08 %22.13 %25.22 %30.11 %Total Liabilities$5.2m
EFFICIENCY
Earnings Waterfall Predictive Oncology Inc.
image
Revenue 1.62 M
Cost Of Revenue 826 K
Gross Profit 798 K
Operating Expenses 11.7 M
Operating Income -10.9 M
Other Expenses -79.3 K
Net Income -10.9 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)2m(826k)798k(12m)(11m)79k(11m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
49.12% GROSS MARGIN
49.12%
-673.69% OPERATING MARGIN
-673.69%
-751.39% NET MARGIN
-751.39%
6022.04% ROE
6022.04%
-245.37% ROA
-245.37%
-433.32% ROIC
-433.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Predictive Oncology Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -10.9 M
Depreciation & Amortization 696 K
Capital Expenditures -9.51 K
Stock-Based Compensation 0
Change in Working Capital -915 K
Others 105 K
Free Cash Flow -11 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Predictive Oncology Inc.
image
POAI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Predictive Oncology Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Court Denies Renovaro Motion for an Expedited Trial in July PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. globenewswire.com - 2 weeks ago
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. globenewswire.com - 3 weeks ago
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. globenewswire.com - 3 weeks ago
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples globenewswire.com - 3 weeks ago
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health" Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing globenewswire.com - 3 weeks ago
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the quarter. globenewswire.com - 1 month ago
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024. globenewswire.com - 2 months ago
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan globenewswire.com - 2 months ago
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth globenewswire.com - 2 months ago
Predictive Oncology Closes Registered Direct Offering PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules. globenewswire.com - 3 months ago
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types globenewswire.com - 3 months ago
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform SAN DIEGO--(BUSINESS WIRE)-- #CertisAI--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis's predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. “The patent marks an important milestone for our company,” said Peter Ellman, President and CEO of Certis. “It substantiates the uniqueness of our proprietary platform and the un. businesswire.com - 4 months ago
8. Profile Summary

Predictive Oncology Inc. POAI

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 8.26 M
Dividend Yield 0.00%
Description Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Contact 2915 Commers Drive, Pittsburgh, MN, 55121 https://www.predictive-oncology.com
IPO Date May 3, 2010
Employees 23
Officers Mr. Raymond F. Vennare Chief Executive Officer & Chairman Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. Senior Vice President of Biologics Mr. Joshua Blacher CPA, M.B.A. Interim Chief Financial Officer Dr. Arlette H. Uihlein FCAP, M.D. Senior Vice President of Translational Medicine & Drug Discovery and Medical Director